Kronos Worldwide, Inc. (NYSE:KRO) today reported net income of $71.8 million, or $.62 per share, in the third quarter of 2024 compared to a net loss of $20.4 million, or $.18 per share, in the third ...
Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma – – Poster presentation to take place ...